SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST is generating significant buzz as the privacy layer on Solana, holding remarkably strong amidst broader market volatility and trending high across crypto discussions. The community is actively touting its low market cap, promising utility with integrations like Zebec Network, and an anticipated revenue-sharing model.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst intense community discussion surrounding the recent inauguration of its Eagle Line pilot production facility and high anticipation for its upcoming earnings report. Investors are keenly watching for updates on solid-state battery commercialization, manufacturing yields, and confirmation of new OEM partnerships, even as broader market sentiment remains volatile.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

FARTCOIN is experiencing a surge in trading and community interest following its recent listing on Arkham Exchange, sparking a polarized discussion between those anticipating further parabolic moves as a top memecoin with "utility" and others highlighting its speculative nature. The crypto community is actively monitoring its volatility and reported whale accumulation within the broader memecoin market.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is surging with community optimism ahead of the 4/20 cultural event, driven by its 'like Bitcoin but way higher' mantra and a vision for global cannabis legalization, fostering a culture of patience and long-term engagement.

Aster is a next-generation decentralized perpetual exchange that combines non-custodial trading with advanced features like hidden orders and multi-chain support. The platform emerged from the merger of Astherus and APX Finance in late 2024, with APX token holders able to migrate their holdings to ASTER.  Aster addresses the gap between centralized and decentralized exchanges by enabling traders to maintain full control of their assets while accessing deep liquidity and CEX-grade trading tools. The platform supports trading of both cryptocurrency perpetuals and U.S. stocks with up to 100x leverage, all settled on-chain in crypto without requiring traditional financial infrastructure.  The platform offers two distinct trading modes to accommodate different user needs. Simple Mode provides one-click, MEV-resistant trading with up to 1001x leverage for beginners, while Pro Mode delivers a full order book with advanced features like automated grid trading and hidden orders that remain invisible until execution.   Aster operates across BNB Chain, Ethereum, Solana, and Arbitrum without requiring bridging, with liquidity pooled across markets to support large trades with minimal slippage. A distinctive feature allows users to deposit yield-generating assets like asBNB or USDF as collateral, earning passive returns while trading, maximizing capital efficiency compared to platforms where collateral sits idle.  Aster received backing from YZi Labs (formerly Binance Labs), which holds a minority stake through a private fund managing over $10 billion on behalf of early Binance executives. Changpeng Zhao, founder of Binance, serves in an advisory role and has personally invested over $2.5 million worth of ASTER tokens.   The ASTER token serves multiple functions including governance rights, staking rewards through liquidity provision, and earning incentives through the platform's points program for traders and liquidity providers.

ASTERION

ASTER is a hot topic as a decentralized exchange (DEX) token, with community discussion centered on a recent significant token burn and perceived strong backing from CZ, fueling both bullish predictions for its potential to rival platforms like Hyperliquid and sharp skepticism about its underlying value and potential for manipulation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after announcing it will stop offering its compounded weight-loss pill due to escalating federal regulatory scrutiny, fueling a polarized community debate between bears predicting a major downfall and bulls anticipating a short squeeze and long-term rebound due to reduced risk and strong underlying business.

Hawaiian Electric Industries, Inc. is a holding company, which engages in electric utility and non-regulated renewable and sustainable infrastructure businesses. The company was founded by C. Dudley Pratt Jr. in 1981 and is headquartered in Honolulu, HI.

Hawaiian Electric Industries, Inc.

Hawaiian Electric Industries is trending as major institutional investors significantly increase their holdings and legislative efforts progress to bolster its financial stability after wildfire settlements, fueling community anticipation for the utility's long-term recovery and potential dividend reinstatement.

Kinder Morgan, Inc. engages in providing pipeline transportation of natural gas services. It operates through the following business segments: Natural Gas Pipelines, Products Pipelines, Terminals, and CO2. The Natural Gas Pipelines segment operates major interstate and intrastate natural gas pipelines and storage systems. The Products Pipelines segment is involved in the operation of refined petroleum products, crude oil, and condensate pipelines. The Terminals segment includes the operation of liquids and bulk terminal facilities that store and handle various commodities. The CO2 segment produces, transports, and markets to oil fields that use CO2 as a flooding medium to increase recovery and production of crude oil from mature oil fields. The company was founded by Richard D. Kinder and William V. Morgan in February 1997 and is headquartered in Houston, TX.

Kinder Morgan Inc - Ordinary Shares - Class P

Kinder Morgan is drawing significant attention following its Q4 earnings, which showed a revenue beat and strong FY25 guidance, boosted by record natural gas pipeline performance and a massive project backlog aimed at surging LNG and AI data center demand. The community is actively debating KMI's long-term growth and reliable dividend against recent upward momentum, with many viewing it as a resilient energy infrastructure play.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is experiencing heightened discussion due to Bitcoin's volatile price action, with the community sharply divided between those predicting an imminent parabolic rally to new highs and others forecasting a significant 'crypto winter' crash based on historical cycles and ETF outflows.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

The FDA's acceptance of Cingulate Inc.'s NDA for its CTx-1301 ADHD treatment, with a PDUFA date of May 31, 2026, combined with anticipated US patent news, is driving community discussion about the stock's criminally low market cap and significant upside potential for its innovative, once-daily solution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the third quarter, according to the company in its most recent 13F...

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5.26% and -0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% - Time to Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.6% - Here's Why...

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>The trial is for the use of Nexiguran Ziclumeran (Nex-Z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.</li><li>The Phase 3 trial was suspended after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue.</li><li>The decision clears the way for Intellia to resume patient enrollment in the study.</li></ul>Shares of Intellia Therapeutics (NTLA) gained more than 13% on Tuesday morning as the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of Nexiguran Ziclumeran (Nex-Z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.A clinical hold is a delay or suspension of an ongoing clinical trial due to serious safety concerns.<h2 class="st-heading-2">Why Did FDA Suspend The Trial?</h2>The clinical hold was imposed in late October 2025 after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue that met the protocol-defined pausing criteria. Since then, Intellia has worked with the FDA to implement study modifications, including enhanced monitoring of liver-related lab tests.“With the clinical hold for MAGNITUDE-2 lifted, our team is focused on resuming patient enrollment as quickly as possible as we seek to advance this potential one-time treatment option for people living with ATTRv-PN,” said John Leonard, Intellia’s President and CEO.MAGNITUDE-2 is a randomized placebo-controlled study assessing the safety and effectiveness of Nex-Z in patients with ATTRv-PN. Following a protocol update, Intellia increased target enrollment to about 60 patients.<h2 class="st-heading-2">What’s Next?</h2>The decision clears the way for Intellia to resume patient enrollment in the study. Intellia said discussions with the FDA are ongoing regarding the separate MAGNITUDE Phase 3 trial of Nex-Z in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and the company will provide an update once a path forward is finalized.Nex-Z is a gene-editing therapy designed to permanently inactivate the TTR gene, which is key in producing a protein called transthyretin. The program has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, highlighting its potential to address serious unmet medical needs.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘high’ message volumes. <a href="https://stocktwits.com/symbol/NTLA">NTLA</a> was among the top trending tickers on the platform at the time of writing.One user believes the development should be good for the sector.<stembedurl>https://stocktwits.com/FredGS/message/642984565</stembedurl>Another user expects the stock to cross $20 by the end of the trading session. It is currently trading close to $15.<stembedurl>https://stocktwits.com/BrokersNY/message/642985076</stembedurl>The stock has gained nearly 50% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/what-triggered-qbts-stock-s-pre-market-rally-today/cmyaCXDR4LL">What Triggered QBTS Stock’s Pre-Market Rally Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About?

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with Nex-Z 

Equity

AI Hits the Factory Floor, Defense Wins Get Bigger, and Gene Editing Regains Momentum

This morning’s news flow highlights how innovation is translating into execution across robotics, industrial automation, defense, and life sciences.

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9% - Time to Buy?

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.9% - Still a Buy...

Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News

NTLAIntellia Therapeutics Inc